Cytokinetics, Incorporated - Common Stock (CYTK)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Aug 21, 2026Investment Snapshot
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 119.0% — good return on equity
- Revenue growing at 377% annually
Cytokinetics, Incorporated - Common Stock (CYTK) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $10.7 billion . Key value metrics: Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Cytokinetics, Incorporated - Common Stock — Fundamental Analysis Summary
On financial health, CYTK shows a moderate Piotroski F-Score of 4/9, and strong return on equity of 119.0% (sector average: -20.1%).
StockPik's composite Value Score for CYTK is 45/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CYTK shows revenue growing at 377% year-over-year, with earnings declining at 33%.